Considering that transgenic mice may have interference with GPC5 due to their genetic background, if we can obtain lung cancer tissues carrying patient mutations again in the future, we will employ the patient-derived xenografts (PDX) model to further study the specific role and mechanism of the mutation in in vivo experiments. The gene discussed is GPC5; the disease is lung carcinoma.